Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.KALEXSYN, a global medicinal chemistry contract research organization, has agreed to provide medicinal chemistry services to drive BioRelix's ongoing research activities for the discovery of new anti-bacterial drugs.
Subscribe to our email newsletter
BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed riboswitches – an innovative class of RNA drug targets found in pathogenic bacteria and fungi.
KALEXSYN CEO David Zimmermann said the company has been a key collaborator on medicinal chemistry strategy and has provided high impact synthetic expertise to BioRelix for several years.
BioRelix CEO Brian Dixon said they chose to work with KALEXSYN because of their expertise and their ability to fully engage in the scientific discovery process with their research team.